162 related articles for article (PubMed ID: 38650534)
21. Risk- and response-adapted strategies for the management of Hodgkin lymphoma.
Remer M; Johnson PW
Chin Clin Oncol; 2015 Mar; 4(1):13. PubMed ID: 25841720
[TBL] [Abstract][Full Text] [Related]
22. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
Mauz-Körholz C; Landman-Parker J; Balwierz W; Ammann RA; Anderson RA; Attarbaschi A; Bartelt JM; Beishuizen A; Boudjemaa S; Cepelova M; Claviez A; Daw S; Dieckmann K; Fernández-Teijeiro A; Fosså A; Gattenlöhner S; Georgi T; Hjalgrim LL; Hraskova A; Karlén J; Kluge R; Kurch L; Leblanc T; Mann G; Montravers F; Pears J; Pelz T; Rajić V; Ramsay AD; Stoevesandt D; Uyttebroeck A; Vordermark D; Körholz D; Hasenclever D; Wallace WH
Lancet Oncol; 2022 Jan; 23(1):125-137. PubMed ID: 34895479
[TBL] [Abstract][Full Text] [Related]
23. Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment?
Maraldo MV; Brodin P; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):297-303. PubMed ID: 23910709
[TBL] [Abstract][Full Text] [Related]
24. Role of Radiation Therapy in the Treatment of Hodgkin Lymphoma.
Gonzalez VJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):244-250. PubMed ID: 28497317
[TBL] [Abstract][Full Text] [Related]
25. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma.
Hoppe BS; Hill-Kayser CE; Tseng YD; Flampouri S; Elmongy HM; Cahlon O; Mendenhall NP; Maity A; McGee LA; Plastaras JP
Ann Oncol; 2017 Sep; 28(9):2179-2184. PubMed ID: 28911093
[TBL] [Abstract][Full Text] [Related]
26. Pulmonary Toxicity Following Proton Therapy for Thoracic Lymphoma.
Nanda R; Flampouri S; Mendenhall NP; Indelicato DJ; Jones LM; Seeram VK; Hoppe BS
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):494-497. PubMed ID: 28872001
[No Abstract] [Full Text] [Related]
27. Treatment of early-stage nonbulky Hodgkin lymphoma.
Straus DJ
Curr Opin Oncol; 2006 Sep; 18(5):432-6. PubMed ID: 16894289
[TBL] [Abstract][Full Text] [Related]
28. Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma.
Timlin C; Loken J; Kruse J; Miller R; Schneider U
Br J Radiol; 2021 May; 94(1121):20200354. PubMed ID: 33237825
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
Vijenthira A; Chan K; Cheung MC; Prica A
Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
[TBL] [Abstract][Full Text] [Related]
30. Proton Therapy for Pediatric Hodgkin Lymphoma.
Wray J; Flampouri S; Slayton W; Joyce M; Sandler E; Morris CG; Li Z; Indelicato DJ; Mendenhall NP; Hoppe BS
Pediatr Blood Cancer; 2016 Sep; 63(9):1522-6. PubMed ID: 27149120
[TBL] [Abstract][Full Text] [Related]
31. [Treatment strategy for patients with Hodgkin lymphoma].
Yoshida I
Rinsho Ketsueki; 2017; 58(10):1973-1982. PubMed ID: 28978839
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy or Combined Modality Therapy for Early-stage Hodgkin Lymphoma.
Torok JA; Wu Y; Chino J; Prosnitz LR; Beaven AW; Kim GJ; Kelsey CR
Anticancer Res; 2018 May; 38(5):2875-2881. PubMed ID: 29715111
[TBL] [Abstract][Full Text] [Related]
33. Individualised Estimation of Quality-adjusted Survival Benefit and Cost-effectiveness of Proton Beam Therapy in Intermediate-stage Hodgkin Lymphoma.
Jones DA; Candio P; Shakir R; Ramroth J; Wolstenholme J; Gray AM; Cutter DJ; Ntentas G
Clin Oncol (R Coll Radiol); 2023 May; 35(5):301-310. PubMed ID: 36732121
[TBL] [Abstract][Full Text] [Related]
34. Clinical and technical considerations for mediastinal Hodgkin lymphoma protontherapy based on a single-center early experience.
Loap P; Goudjil F; Dendale R; Kirova Y
Cancer Radiother; 2021 Dec; 25(8):779-785. PubMed ID: 34275748
[TBL] [Abstract][Full Text] [Related]
35. Proton therapy in a pediatric patient with stage III Hodgkin lymphoma.
Holtzman A; Flampouri S; Li Z; Mendenhall NP; Hoppe BS
Acta Oncol; 2013 Apr; 52(3):592-4. PubMed ID: 23477362
[No Abstract] [Full Text] [Related]
36. Modern treatment of Hodgkin lymphoma.
Bartlett NL
Curr Opin Hematol; 2008 Jul; 15(4):408-14. PubMed ID: 18536581
[TBL] [Abstract][Full Text] [Related]
37. Can treatment of pediatric Hodgkin's lymphoma be improved by PET imaging and proton therapy?
Knäusl B; Lütgendorf-Caucig C; Hopfgartner J; Dieckmann K; Kurch L; Pelz T; Pötter R; Georg D
Strahlenther Onkol; 2013 Jan; 189(1):54-61. PubMed ID: 23161118
[TBL] [Abstract][Full Text] [Related]
38. SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma.
Watkins MP; Fanale MA; Bartlett NL
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):81-90. PubMed ID: 29366607
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy only in early stage Hodgkin lymphoma: more relapses but the same survival--what to do?
Connors JM
Curr Hematol Malig Rep; 2014 Sep; 9(3):217-21. PubMed ID: 24838494
[TBL] [Abstract][Full Text] [Related]
40. Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold.
Rechner LA; Maraldo MV; Vogelius IR; Zhu XR; Dabaja BS; Brodin NP; Petersen PM; Specht L; Aznar MC
Radiother Oncol; 2017 Oct; 125(1):41-47. PubMed ID: 28838605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
